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126Statin therapy after infrainguinal bypass surgery for
critical limb ischemia is associated with improved
5-year survival
Bjoern D. Suckow, MD, MS,a Larry W. Kraiss, MD,a Andres Schanzer, MD,b David H. Stone, MD,c
Jeffrey Kalish, MD,d Randall R. DeMartino, MD,c Jack L. Cronenwett, MD,c and
Philip P. Goodney, MD, MS,c for the Vascular Study Group of New England, Salt Lake City, Utah; Worcester
and Boston, Mass; and Hanover, NH
Objective: Although statin therapy has been linked to fewer short-term complications after infrainguinal bypass, its effect
on long-term survival remains unclear. We therefore examined associations between statin use and long-term mortality,
graft occlusion, and amputation after infrainguinal bypass.
Methods: We used the Vascular Study Group of New England registry to study 2067 patients (71% male; mean age, 67 6
11 years; 67% with critical limb ischemia [CLI]) who underwent infrainguinal bypass from 2003 to 2011. Of these, 1537
(74%)were on statins perioperatively and at 1-year follow-up, and 530 received no statin.We examined crude, adjusted, and
propensity-matched rates of 5-year surviva1, 1-year amputation, graft occlusion, and perioperative myocardial infarction.
Results: Patients taking statins at the time of surgery and at the 1-year follow-up were more likely to have coronary
disease (38% vs 22%; P < .001), diabetes (51% vs 36%; P < .001), hypertension (89% vs 77%; P < .001), and prior
revascularization procedures (50% vs 38%; P < .001). Despite higher comorbidity burdens, long-term survival was better
for patients taking statins in crude (risk ratio [RR], 0.7; P < .001), adjusted (hazard ratio, 0.7; P [ .001), and
propensity-matched analyses (hazard ratio, 0.7; P [ .03). In subgroup analysis, a survival advantage was evident in
patients on statins with CLI (5-year survival rate, 63% vs 54%; log-rank, P [ .01) but not claudication (5-year survival
rate, 84% vs 80%; log-rank,P[ .59). Statin therapywas not associated with 1-year rates of major amputation (12% vs 11%;
P [ .84) or graft occlusion (20% vs 18%; P [ .58) in CLI patients. Perioperative myocardial infarction occurred more
frequently in patients on a statin in crude analysis (RR, 2.2; P[ .01) but not in the matched cohort (RR, 1.9; P[ .17).
Conclusions: Statin therapy is associated with a 5-year survival beneﬁt after infrainguinal bypass in patients with CLI.
However, 1-year limb-related outcomes were not inﬂuenced by statin use in our large observational cohort of patients
undergoing revascularization in New England. (J Vasc Surg 2015;61:126-33.)Peripheral arterial disease (PAD) affects nearly 30%
of Americans aged >65 years and is predicted to increase
in prevalence over the next decade.1-3 Patients with
PAD face a sixfold increase in mortality that is attributed
to atherosclerosis of the coronary and cerebral vasculature
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://dx.doi.org/10.1016/j.jvs.2014.05.093For patients with atherosclerosis, 3-hydroxy-3 methyl-
glutaryl-coenzyme A reductase inhibitor (statin) therapy
has proven effective in combating endothelial inﬂammation
and has been shown to stabilize arterial plaque.6 The Justi-
ﬁcation for the Use of Statins in Primary Prevention: An
Intervention Trial Evaluating Rosuvastatin (JUPITER)
trial demonstrated a survival beneﬁt associated with
statins,7 and a global recommendation has therefore been
made that patients with PAD should be on statin medica-
tion for secondary prevention of adverse events.8
Among patients who undergo lower extremity bypass
surgery for severe PAD, small trials and observational data
sets suggest that statin therapy may have protective effects
on bypass graft patency and on patient survival.9-11 Howev-
er, these studies only ascertained statin use at the time of sur-
gery and were restricted in size and generalizability. At
present, limited data exist regarding the possible protective
effect of prolonged statin use in patients who have under-
gone lower extremity bypass surgery for severe PAD.
The aim of this study, therefore, was to determine the ef-
fect of long-term statin use after infrainguinal bypass grafting
on patient-related and graft-related outcomes. Accordingly,
we studied patients who underwent infrainguinal bypass sur-
gery in a large observational data set that contains information
VSGNE Database Jan 2003 – Dec 2011
4,613
Lower Extremity Bypass Procedures
• 82 (2%) Missing Follow-Up Data
• 35 (1%) Statin Intolerant
• 1,694 (37%) Incomplete Statin Data
• 310 (7%) Non-Primary Bypasses2,492 
Patients with Statin-Use Data
Exclude
Exclude • 151 (6%) Statin only at 1-yr f/u
• 274 (11%) Statin only peri-op
530 (26%)
Never on Statin
1,537 (74%)
Statin peri-operatively 
and 1-yr follow-up
2,067 Patients for Analysis
Fig 1. This ﬂowchart depicts the exclusion from analysis of individuals within the Vascular Study Group of New
England (VSGNE) database and how the ﬁnal study cohort was created.
JOURNAL OF VASCULAR SURGERY
Volume 61, Number 1 Suckow et al 127regarding the use and duration of statin therapy. In this
manner, we hoped to ascertain whether the physiologic protec-
tive effects of statin therapy translate into a real-world improve-
ment in patient survival, myocardial infarction (MI) rates after
surgery, or prolonged graft patency and limb salvage.
METHODS
Institutional Review Board permission to use deidenti-
ﬁed data from the Vascular Study Group of New England
(VSGNE) was obtained from the Protection of Human
Subjects of the Geisel School of Medicine at Dartmouth.
Patient consent did not need to be obtained given the dei-
dentiﬁed nature of the database.
Database and patients. The data for this study were
obtained from the prospectively collected quality initiative of
the VSGNE,12 reﬂecting cases of 115 surgeons from 23
different institutions, ranging from community hospitals to
academic and tertiary referral centers. Physicians or research
personnel, or both, abstracted data at three distinct time pe-
riods for each patient: just before surgery, at hospital discharge
from the index surgery, and at 1-year follow-up visits. The
VSGNE data registry is audited for completeness annually.
Patient cohort and long-term statin use. All patients
who underwent open infrainguinal bypass surgery between
January 1, 2003, and December 31, 2011, were eligible
for study inclusion. Indications for bypass were critical limb
ischemia (CLI), deﬁned as rest pain or ischemic tissue loss,
or lifestyle-limiting claudication. We only studied the ﬁrst
bypass procedure for each patient because subsequent by-
passes can act as confounders due to within-patient depen-
dence.13 Patients without sufﬁcient follow-up data (2%) or
with documented statin intolerance (1%) were excluded.
Because statin use was the primary independent variable
of interest in this study, we excluded any patient who had
incomplete documentation of statin use; speciﬁcally, 37%of eligible patients (1694 of 4613) lacked documentation
of statin use preoperatively, at the time of hospital discharge,
or at long-term follow-up. Further, our objective was to elicit
the effect of prolonged statin use; therefore, we only studied
patients who were documented to be on a statin both perio-
peratively and at the 1-year follow-up (Fig 1). Outcomes
were compared between this group (n¼ 1537) and those pa-
tients who were never on a statin (n¼ 530). The proportion
of patients on a long-term statin did not vary signiﬁcantly
between medical centers, ranging fromw70% to 80%.
Propensity-matched cohort. Statin therapy in this
observational data set was not assigned randomly but therapy
wasprovidedat thediscretionof the treatingphysician.Toac-
count for the potential confounding effect of statin use as an
independent variable, we used propensity-matchingmethods
to establish similar patient cohorts.14 We ﬁrst applied all
available patient and operative data to establish a logistic
regression model (Supplementary Table I, online only),
which predicted the likelihood that any given patient would
be on a statin long-term (perioperatively and at 1 year after
surgery) according to the individual patient’s characteristics.
Each patient was assigned a propensity score based on
the number of applicable variables from the model. Between
each patient group, those on a statin long-term and those
never on a statin, patients were stratiﬁed by propensity score
and then equally matched as described by Becker et al.15
With this technique, we were able to match an equal
number of patients who were not on a statin with those
who were on a statin yet at baseline had the same propen-
sity (based on their individual characteristics) for being
prescribed statin therapy. This process created two groups
of patients who had comparable demographic, operative,
and other characteristics and only differed in their use of
statin therapy. After creation of our matched cohort, we
used c2 and t-test comparisons to compare results of the
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propensity-matched cohort. This proved that all measured
covariates were equalized between matched groups.
Further, we compared the patients in the statin and no-
statin groups who were matched (n ¼ 862) with those
who were not matched (n ¼ 1205) and found they were
similar in baseline patient and operative demographics.
Outcome measures. Our primary outcome measure
was patient survival. To ascertain the date of death, we
linked the VSGNE data set to the Social Security Death
Index.16 This allowed us to track survival for up to
7 years after the index bypass procedure. Mean follow-up
time for survival was 3.2 6 2.0 years.
Secondary outcomes were freedom from graft occlusion,
freedom from major amputation, including above-knee and
below-knee amputations, and perioperative MI. These
events were abstracted directly from the VSGNE database,
which contacts patients 9 to 15 months after the index pro-
cedure to ascertain outcome events. The mean follow-up
time for graft occlusion and major amputation was 304 6
174 days. MI was deﬁned as new changes on ST and
T waves, troponin elevation, or documentation by echocar-
diogram or other imaging modality, and was assessed only
during the hospitalization for the bypass. All outcome mea-
sures were compared between two groups: patients who
were on a statin long-term and patients who were never
on a statin. Subgroup analyses were performed, stratiﬁed
by the indication for surgery (CLI vs claudication).
Statistical analysis. For patient demographics and
operative characteristics, we used c2 analysis for categoric
variables and t-test (paired t-test for matched groups) or
analysis of variance for continuous variables to compare
the two groups. The c2 and logistic regression analysis
was used to compare MI rates. To analyze mortality, graft
occlusion, and major amputation rates, we used life-table
analysis. Survival curves were generated by Kaplan-Meier
technique. Log-rank tests were used to determine signiﬁ-
cance levels between comparisons, and Cox proportional
hazard models determined predictive variables. Means were
used for continuous data analysis after conﬁrmation of
normal distribution of continuous data. Variables of sig-
niﬁcance in regression and Cox analysis were chosen using
stepwise backward elimination.
P values of <.05 were considered signiﬁcant, and 95%
conﬁdence intervals (CI) were reported. All analyses were
performed using Excel (Microsoft Corp, Redmond, Wash)
and STATA (StataCorp LP, College Station, Tex) software.
RESULTS
Patient and operative characteristics. Of the 2067
patients who met our inclusion criteria, 1537 (74%) were
taking a statin perioperatively and at the 1-year follow-
up, whereas 530 (26%) were never on a statin. Patients
taking a statin were more commonly male (72% vs 67%;
P ¼ .03) and had a higher body mass index (28.2 vs
25.8 kg/m2; P < .001; Table I). Similarly, they had a
higher prevalence of comorbid medical conditions, such as
hypertension (89% vs 77%; P < .001), diabetes mellitus(51% vs 36%; P < .001), and coronary artery disease (38%
vs 22%; P < .001). Patients on a statin more commonly had
prior carotid and peripheral arterial interventions (Table I)
and were more often prescribed other cardioprotective
medications such as aspirin (80% vs 61%; P < .001), a
b-blocker (81% vs 74%; P ¼ .001), or clopidogrel (14% vs
6%; P < .001). Operative characteristics are compared in
Table II. Speciﬁcally, laterality of graft placement, conduit
type used, and bypass graft origin or target were similar
between patients who were and were not on a statin.
Characteristics of the matched cohort. By applica-
tion of the stratiﬁed propensity-score method, we success-
fully matched 431 patients in the statin group with 431
patients who were never on a statin. Table I compares
characteristics between the propensity-matched patients
who were and were not treated with statins. As is evident
from the Table, the two groups had a similar proportion of
patients with hypertension (79% vs 79%; P ¼ .93) and dia-
betes (39% vs 37%; P ¼ .53). Similarly, a comparable
number of patients were taking b-blockers (71% vs 74%; P ¼
.36), aspirin (63% vs 63%; P ¼ 1), or clopidogrel (7% vs 7%;
P¼ .89). The number of prior carotid and peripheral arterial
procedures was also similar between groups after propensity-
score matching (Table I). Operative characteristics remained
balanced and comparable between the statin and no-statin
groups within the matched cohort (Table II).
Survival. The overall survival rate for patients treated
with statins was 96% at 1 year, 67% at 5 years, and 56% at
7 years. For patients not treated with statins, survival was
94% at 1 year, 59% at 5 years, and 46% at 7 years (log-
rank P < .001 vs patients treated with statins; Fig 2).
Once we adjusted for confounding variables by Cox pro-
portional hazard analysis, long-term statin use subsisted as a
signiﬁcant protective variable against death (hazard ratio
[HR], 0.7; 95% conﬁdence interval [CI], 0.6-0.9; P ¼
.001; Table III). Female patients also had a lower likeli-
hood of dying (HR, 0.7; P < .001). Among the risk factors
for death were older age (HR, 1.04 per year; P < .001),
heart failure (HR, 1.3; P¼ .03), coronary disease (HR, 1.4;
P ¼ .001), diabetes (HR, 1.5; P < .001), postoperative MI
(HR, 1.8; P < .001), and CLI (HR, 1.5; P ¼ .004).
We found a similar trend in the propensity-matched
cohort. Survival rates were 96% at 1 year, 67% at 5 years,
and 54% at 7 years for statin users compared with 95% at
1 year, 63% at 5 years, and 49% at 7 years for those not using
statins (log-rank, P ¼ .02; Fig 2). The Cox proportional
hazard analysis showed the use of a statin persisted as the
only signiﬁcant protective variable against death (HR, 0.7;
95% CI, 0.6-0.9; P ¼ .03). Older age (HR, 1.06 per year;
P < .001), CLI (HR, 1.6; P ¼ .008), and dialysis (HR,
3.9; P ¼ .01) were among the variables associated with a
higher risk of death in the matched cohort (Table III).
Subanalysis of survival by indication. As mentioned
previously, CLI was an independent variable predictive of
survival in the Cox models for the crude and matched co-
horts. We therefore divided both cohorts by indication for
bypass surgery (CLI vs claudication). As shown in Fig 2,
patients who underwent infrainguinal bypass for CLI had
Table I. A comparison of baseline patient characteristics between patients who were never on a statin (no-statin group)
and those who were on long-term therapy (statin group)
Variablea
All
(N ¼ 2067)
Unmatched cohort Propensity-matched cohort
Statin group
(n ¼ 1537)
No-statin group
(n ¼ 530) P
Statin group
(n ¼ 431)
No-statin group
(n ¼ 431) P
Male gender 1356 (71) 1103 (72) 353 (67) .03 278 (65) 286 (66) .57
White race 2015 (97) 1498 (97) 517 (98) .54 421 (98) 419 (97) .76
BMI, kg/m2 27.6 6 6.0 28.2 6 5.8 25.8 6 6.2 <.001 26.9 6 5.4 26.4 6 6.5 .24
Preoperatively
Living at home 2000 (97) 1497 (98) 503 (95) .002 416 (97) 414 (96) .72
Independently ambulatory 1669 (81) 1265 (82) 404 (76) .01 343 (80) 341 (79) .46
Age, years 67.2 6 11.6 67 6 10.5 68 6 12.7 .09 67.4 6 11.5 67.7 6 12.5 .72
Smoking (prior or current) 1752 (85) 1315 (86) 437 (83) .1 357 (83) 362 (84) .72
Hypertension 1781 (86) 1347 (89) 407 (77) <.001 340 (79) 339 (79) .93
COPD 547 (26) 404 (26) 143 (27) .75 115 (27) 114 (26) .94
Diabetes 983 (48) 791 (51) 192 (36) <.001 167 (39) 158 (37) .53
Coronary disease 696 (34) 579 (38) 117 (22) <.001 91 (21) 93 (22) .87
Creatinine >1.8 mg/dL 152 (8) 117 (8) 35 (7) .57 24 (6) 28 (7) .57
b-Blocker 1637 (79) 1245 (81) 392 (74) .001 306 (71) 318 (74) .36
Aspirin 1543 (75) 1222 (80) 321 (61) <.001 273 (63) 273 (63) 1
Clopidogrel 241 (12) 210 (14) 31 (6) <.001 29 (7) 30 (7) .89
Congestive heart failure 272 (13) 214 (14) 58 (11) .08 34 (8) 38 (9) .62
CLI 1389 (67) 1001 (65) 388 (73) .001 296 (69) 296 (69) 1
Previous
Arterial bypass 642 (31) 502 (33) 140 (26) .007 140 (32) 124 (29) .24
Angioplasty/stent 549 (27) 450 (29) 99 (19) <.001 92 (21) 88 (20) .74
Major amputation 85 (4) 61 (4) 24 (5) .57 18 (4) 16 (4) .73
Carotid endarterectomy 209 (10) 179 (12) 30 (6) <.001 29 (7) 27 (6) .78
Aneurysm repair 117 (6) 99 (6) 18 (3) .009 17 (4) 16 (4) .86
Preoperative imaging
Duplex 864 (42) 650 (42) 214 (40) .44 172 (40) 178 (41) .68
MRA 140 (7) 101 (7) 39 (7) .53 35 (8) 36 (8) .9
CTA 465 (23) 349 (23) 116 (22) .71 106 (25) 106 (25) 1
Angiography 1404 (72) 1058 (73) 346 (70) .32 303 (70) 298 (69) .71
Risk scoreb 0.79 6 0.003 0.68 6 0.008 <.001 0.68 6 0.008 0.68 6 0.008 .53
BMI, Body mass index; CLI, critical limb ischemia; CTA, computed tomography angiography; COPD, chronic obstructive pulmonary disease;MRA,magnetic
resonance angiography.
aContinuous data are shown as the mean 6 standard deviation and categoric data as number (%).
bPropensity for obtaining statin.
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claudication. Further, among CLI patients, those who were
on a statin had better 5-year survival than those not on a
statin (60% vs 51%; log-rank, P ¼ .003). There was no
difference in 5-year survival between patients who were and
were not treated with statins when the indication for sur-
gery was claudication (81% vs 82%; log-rank, P ¼ .92).
A similar trend was noted within the matched cohort.
For patients with CLI as their indication for bypass, those
on a statin maintained a 5-year survival beneﬁt compared
with those not on a statin (63% vs 54%; log-rank, P ¼
.01). However, for patients in the matched cohort who
had claudication as the indication for bypass, survival did
not vary based on statin use (84% vs 80%, log-rank, P ¼
.59). The Kaplan-Meier curves for patient survival within
the matched cohort are also included in Fig 2, subdivided
by indication for bypass.
Secondary outcomes. The crude incidence of postop-
erative MI was twice as high among patients treated with
statins (70 of 1527 [4.6%]) compared with patients not
treated with statins (11 of 530 [2.1%]; risk ratio, 2.2;P ¼ .01). In logistic regression analysis, statin use remained
linked with a higher incidence of MI (odds ratio [OR], 2.4;
P ¼ .04). Further risk factors for MI after infrainguinal
bypass included female gender (OR, 1.9; P ¼ .02), diabetes
(OR, 2.9; P ¼ .001), coronary artery disease (OR, 2.6; P ¼
.001), chronic obstructive pulmonary disease (OR, 2.0;
P ¼ .02), CLI (OR, 3.1; P ¼ .02), older age (OR, 1.03
per year; P ¼ .01), and more distal bypass targets (OR,
3.2; P ¼ .003). The logistic regression model is summa-
rized in Supplementary Table II (online only). Within the
matched cohort, the incidence of MI was no longer sta-
tistically signiﬁcant between patients who were and were
not on long-term statin therapy (risk ratio, 1.9; P ¼ .17).
Major lower extremity amputation rates were nearly
identical for patients who were and were not on a statin
(7% vs 8%, respectively; P ¼ .4). Fig 3 demonstrates no dif-
ference (log-rank, P ¼ .4) in major amputations between
statin treatment groups at 1 year of follow-up. For patients
who underwent bypass for CLI, major amputation rates at
1 year were slightly higher, although no different by statin
use (12% vs 11%; P ¼ .84).
Table II. A comparison of operative characteristics between patients who were never on a statin (no-statin group) and
those who were on long-term therapy (statin group)
Variables
All
(N ¼ 2067),
No. (%)
Unmatched cohort Propensity-matched cohort
Statin group
(n ¼ 1537),
No. (%)
No-statin group
(n ¼ 530),
No. (%) P
Statin group
(n ¼431),
No. (%)
No-statin group
(n ¼ 431),
No. (%) P
Graft sidedright 1002 (48) 743 (48) 259 (49) .83 227 (53) 221 (51) .68
Graft origin
External iliac 42 (2) 32 (2.1) 10 (1.9) .79 8 (2) 7 (2) .79
CFA 1365 (66) 1032 (67) 333 (63) .08 278 (65) 283 (66) .72
PFA 58 (2.8) 50 (3.3) 8 (1.5) .04 9 (2) 9 (2) 1
SFA 417 (20) 285 (19) 132 (25) .002 96 (22) 95 (22) .94
AK-Pop 83 (4) 60 (3.9) 23 (4.4) .66 23 (5) 20 (5) .64
BK-Pop 94 (4.6) 73 (4.8) 21 (4) .46 16 (4) 16 (4) 1
Graft recipient
AK-Pop 529 (26) 408 (27) 121 (23) .09 102 (24) 109 (25) .58
BK-Pop 728 (35) 543 (35) 185 (35) .88 157 (36) 152 (35) .72
TP trunk 84 (4.1) 65 (4.2) 19 (3.6) .52 10 (2) 16 (4) .23
Tibial vessels 485 (23) 343 (22) 142 (27) .04 117 (27) 110 (26) .59
Tarsal/pedal vessels 183 (9) 132 (9) 51 (10) .47 35 (8) 35 (8) 1
Conduit type
Prosthetic 541 (26) 408 (27) 133 (25) .51 98 (23) 119 (28) .1
Leg vein (GSV or SSV) 1391 (67) 1016 (66) 375 (71) .05 297 (69) 293 (68) .77
Arm vein (cephalic or basilic) 44 (2.1) 35 (2.3) 9 (1.7) .43 12 (3) 8 (2) .37
Completion study performeda 1230 (60) 900 (59) 330 (62) .13 266 (61) 256 (59) .49
AK, Above knee; BK, below knee; CFA, common femoral artery; GSV, great saphenous vein; PFA, profunda femoris artery; Pop, popliteal; SFA, superﬁcial
femoral artery; SSV, short saphenous vein; TP, tibial-peroneal.
aDuplex or angiogram.
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between statin users and statin nonusers (16% vs 16%;
P ¼ .94). Freedom from graft occlusion was similar during
the entire duration of follow-up between groups (log-rank,
P ¼ .99; Fig 4). Among CLI patients, 1-year graft occlu-
sion rates were somewhat higher but did not signiﬁcantly
differ between those who were and were not receiving
statin therapy (18% vs 20%; P ¼ .58).
DISCUSSION
Within our observational cohort of patients who
underwent infrainguinal bypass for occlusive disease, we
examined associations between the use of prolonged postop-
erative statin therapy and graft and patient-speciﬁc outcomes:
First, we found that patients who took statin therapy for
the year after their revascularization procedures had a sur-
vival beneﬁt not only throughout that year but also main-
tained a signiﬁcant survival advantage up to 7 years later.
Second, we found that this survival beneﬁt was concen-
trated in patients who underwent bypass for CLI rather
than claudication.
Third, although overall survival differed by statin treatment
groups, we were unable to identify a difference in graft-speciﬁc
or limb-speciﬁc outcomes (graft occlusion or major amputa-
tion rates) at 1 year after bypass between individuals who
were and were not on prolonged postoperative statin therapy.
The use and effect of statin therapy has become a recent
topic of investigation for patients with CLI. Schanzer et al10
queried the randomized cohort from the Edifoligide for the
Prevention of Infrainguinal Vein Graft Failure (PREVENT)III trial with regards to statin therapy. Among these patients
who underwent infrainguinal bypass for CLI with vein
conduit that was or was not transfected with edifoligide,
the authors found that statin use was an independent predic-
tor for 1-year survival. In fact, the 30% reduction in the rela-
tive risk of mortality for patients on a statin in this study is
identical to the 30% reduction we found in our cohort.
Several smaller retrospective series have noted similar
trends. Ward et al11 found that preoperative statin use in
446 patients who underwent infrainguinal bypass for occlu-
sive disease was independently associated with improved 5-
year survival. Aiello et al9 discovered that within a cohort
of CLI patients who underwent endovascular treatment,
statin therapy was associated with decreased mortality,
increased limb salvage, and increased primary vessel patency
rates at 2 years. Lastly, a review fromDosluoglu et al17 linked
statin therapy to improved survival but not limb salvage or
patency rates in patients who underwent open or endovascu-
lar lower extremity revascularization.
Our study builds on these existing data in several ways.
First, the series mentioned above were only able to assess
statin use at the time of the index procedure. The Heart
Protection Study Group, however, has demonstrated that
statin use needs to be prolonged to be efﬁcacious and
that its protective effect dissipates upon discontinuation.18
Therefore, we studied those patients who had long-term
postoperative exposure to statins and obtained results
that echo those of the Heart Protection Study Group. In
addition, we linked our survival data to the Social Security
Death Index and found that the survival advantage of statin
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Fig 2. Kaplan-Meier curves comparing patient survival after the index bypass procedure between those who were never on
a statin (No Statin) and those who were on long-term postoperative statin therapy (Statin) are shown for (left) the
unmatched cohort and (right) the propensity-matched cohort. The (top row) graphs depict individuals who underwent
bypass grafting for critical limb ischemia (CLI) and claudication, the (middle row) graphs show only those who underwent
bypass for CLI, and the (bottom row) graphs show those who underwent bypass for claudication. SE, Standard error.
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extremity bypass.
Second, our study did not show a beneﬁt in limb salvage
or graft occlusion rates despite prolonged statin therapy.
Within the PREVENT III cohort, statin use at the time of
surgery was similarly not associated with graft-speciﬁc or
limb-speciﬁc outcomes. Although powered to detect a rela-
tionship between statin use and limb-speciﬁc or graft-speciﬁc
outcomes, the lack of an effect in our studymay have resultedbecause the long-term outcome analysis >1 year focused on
death alone, whereas bypass graft outcomes were assessed at
1 year. Our future work will aim to use linked clinical claims
data sets to ease access to longer-term follow-up for bypass-
related outcomes to examine this hypothesis.
Third, we noted that patients within our cohort who
were on long-term statin therapy also had a higher incidence
of perioperative MI. Given the observational nature of our
data set, the decision to initiate statin therapy in a patient
Table III. Cox proportional hazards model lists all of
the variables signiﬁcantly associated with patient mortality
for the entire cohort and for the propensity-matched
cohort only
Variable HR 95% CI P
Unmatched cohort
Patient taking statin 0.7 0.6-0.9 .001
Autologous GSV used for conduit 0.7 0.5-0.8 <.001
Female gender 0.7 0.6-0.9 .002
Age (additional risk per year of age) 1.04 1.03-1.06 <.001
History of
CHF 1.3 1.03-1.7 .03
CAD 1.4 1.1-1.7 .001
DM 1.5 1.2-1.8 <.001
COPD 1.5 1.2-1.8 <.001
Bypass performed for CLI 1.5 1.1-1.9 .004
Creatinine >1.78 mg/dL 1.8 1.3-2.3 <.001
Propensity-matched cohort
Patient taking statin 0.7 0.6-0.9 .03
Age (additional risk per year of age) 1.06 1.04-1.07 <.001
History of
CHF 2 1.3-2.9 .001
COPD 1.6 1.2-2.1 .002
Bypass performed for CLI 1.6 1.1-2.3 .008
Patient on dialysis 3.9 1.4-11 .01
Distal anastomosis to
TP trunk 4.3 1.9-10 <.001
Tibial vessels 1.5 1.1-2 .01
Creatinine >1.78 mg/dL 2.6 1.8-3.9 <.001
CAD, Coronary artery disease; CHF, congestive heart failure; CI, conﬁ-
dence interval; CLI, critical limb ischemia; COPD, chronic obstructive
pulmonary disease; DM, diabetes mellitus; GSV, great saphenous vein; HR,
hazard ratio; TP, tibial-perineal.
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Fig 3. Kaplan-Meier curve shows the freedom from major below-
knee or above-knee amputation, compared between individuals who
never took a statin (No Statin Group) and those who received long-
term postoperative statin therapy (Statin Group). SE, Standard error.
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Fig 4. Kaplan-Meier curve shows the freedom from lower extremity
bypass graft occlusion compared between individuals who never
took a statin (No Statin Group) and those who received long-term
postoperative statin therapy (Statin Group). SE, Standard error.
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can therefore surmise that statin therapy is an indirect marker
for poor cardiovascular health, meaning that treating physi-
cians are able to discern which patients require this medica-
tion and appropriately prescribe it. Supporting this fact is
that in our propensity-matched cohort, amongwhom patient
comorbidities were equally accounted for, no difference was
seen in MI rates between statin users and nonusers.
Furthermore, the patients who were not taking statins
appeared to be less commonly ambulating independently,
less commonly taking antiplatelet or b-blocker therapy,
and more commonly presented with CLI. Taking into
account the higher rates of comorbid medical diagnoses
in the statin patients, such as hypertension or coronary dis-
ease, we believe that statin therapy in our data set could be
a marker for access to health care. Because access to health
care could also improve survival, we again used a matching
model in an attempt to equalize the groups and home in on
the direct association between statin use and outcomes.
However, unmeasured differences, such as insurance type,
education level, or socioeconomic background, may still
exist between the groups that would best be accounted
for with prospective randomization.
At present, no randomized controlled data exist to
speciﬁcally analyze the effect of statin therapy on survival
and limb salvage in CLI patients who undergo revasculariza-
tion. By applying propensity score-matching techniques, wewere able to account and sufﬁciently control for the variation
that inherently exists among patients in nonrandomized
studies and large data sets. In this manner, our study best ap-
proaches the outcomes of a randomized trial without the
cost and time inherent to such an undertaking.Our ﬁndings,
taken in aggregate with previous reports, demonstrate that
statin therapy is associated with better patient survival
among those who undergo lower extremity bypass for CLI
and that such patients therefore warrant prolonged postop-
erative statin treatment. Statin use in claudicant patients who
undergo lower extremity bypass proved noninferior, sug-
gesting that providers may judiciously assess the risks and
beneﬁts of statin use for each patient’s individual situation.
The effect of statin therapy on graft-speciﬁc and limb-
speciﬁc outcomes, however, remains elusive and may warrant
a dedicated controlled investigation. Moreover, we were sur-
prised to discover that of all the patients who underwent lower
extremitybypass inNewEngland throughoutour studyperiod,
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intermittently. Therefore, prolonged statin therapy will be an
integral part of our future quality improvement endeavors.
Our study has other limitations. First, the use of statin
medication is assessed at distinct time points within our data-
base. Although our statin cohort was abstracted to be taking
this medication perioperatively and also at the 1-year follow-
up, we cannot determine whether the patients remained
compliant in the interim or whether statin intolerance contrib-
uted to difﬁculties with long-term adherence to statin therapy.
Second, our database does not measure lipid levels
of patients, and we therefore cannot correlate improved
survival with lower lipid levels. However, large randomized
trials, such as the Justiﬁcation for the Use of Statins in
Primary Prevention: An Intervention Trial Evaluating
Rosuvastatin (JUPITER) trial, demonstrated survival
beneﬁt regardless of lipid levels.7
Third, we cannot ascertain the direct indication for
which statin therapy was prescribed in our patients.
Fourth, most of our cohort is Caucasian, with an
under-representation of other racial and ethnic groups.
Lastly, our follow-up time for limb and graft-related
outcomes is limited to 1 year, leaving the question whether
statin therapy may indeed affect these outcomes in a longer
time frame.
CONCLUSIONS
Prolonged postoperative statin therapy is associated
with better survival in patients who undergo lower extrem-
ity bypass surgery for CLI in our crude and propensity-
matched analyses of data from a large, regional, quality
improvement collaborative. However, statin therapy was
not associated with bypass graft occlusion or major lower
extremity amputation rates in our graft-related assessments
performed 1 year after revascularization. Future quality
improvement initiatives should develop systematic efforts
to help surgeons and cardiovascular physicians incorporate
statin therapy into the care of PAD patients facing lower
extremity revascularization for CLI.
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Supplementary Table I (online only). Logistic
regression model listing all of the variables that were
signiﬁcantly associated with the likelihood of a patient
receiving long-term statin therapy (ie, perioperatively and
at 1-year follow-up)
Variable OR 95% CI P
Bypass performed for CLI 0.7 0.5-0.9 .005
Female gender 0.7 0.6-0.9 .005
BMI (increased odds
per 1-unit increase)
1.04 1.02-1.06 <.001
History of
Diabetes mellitus 1.5 1.2-1.9 .001
CAD 1.8 1.4-2.4 <.001
Hypertension 2 1.5-2.7 <.001
Arterial bypass surgery 1.3 1.04-1.7 .02
Angioplasty/stent 1.4 1.1-1.9 .02
Carotid endarterectomy 1.8 1.1-2.7 .01
Aneurysm repair 2 1.1-3.6 .02
Patient taking
Clopidogrel 1.6 1.04-2.4 .03
Aspirin 2 1.6-2.5 <.001
BMI, Body mass index; CAD, coronary artery disease; CI, conﬁdence
interval; OR, odds ratio.
Supplementary Table II (online only). Logistic
regression model listing all of the variables that were
signiﬁcantly associated with a myocardial infarction (MI)
before hospital discharge from index lower extremity
bypass procedure.
Variable OR 95% CI P
Age (additional risk per year
of age)
1.03 1.01-1.06 .01
Female gender 1.9 1.1-3.3 .02
History of COPD 2 1.1-3.5 .02
Bypass target to tibial vessels 2.3 1.3-4.2 .006
Patient taking statin 2.4 1.04-5.4 .04
History of CAD 2.6 1.5-4.5 .001
History of DM 2.9 1.6-5.4 .001
Bypass performed for CLI 3.1 1.2-8.0 .02
Bypass target to tarsal/pedal
vessels
3.2 1.5-7.0 .003
CAD, Coronary artery disease; CI, conﬁdence interval; CLI, critical limb
ischemia; COPD, chronic obstructive pulmonary disease; DM, diabetes
mellitus; OR, odds ratio.
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